Table 1 Clinicopathologic characteristics of patients with ER + PR+, ER + PR-, ER-PR+ and ER-PR- tumors
ER + PR+ (N = 4651) | ER-PR+ (N = 90) | ER-PR- (N = 1758) | ER + PR- (N = 481) | |||||
|---|---|---|---|---|---|---|---|---|
Age, median (range) | 47 (20-90) | 48 (22-72) | 49 (21-85) | 54 (27-84) | ||||
Menopause | ||||||||
Postmenopause | 1489 | (32.4%) | 34 | 38.6% | 836 | (48.4%) | 319 | (67.3%) |
Premenopause | 3110 | (67.6%) | 54 | 61.4% | 893 | (51.6%) | 155 | (32.7%) |
Uknown | 52 | 2 | 29 | 7 | ||||
Operation | ||||||||
MRM | 1363 | (29.3%) | 40 | (44.4%) | 585 | (33.3%) | 171 | (35.6%) |
BCS | 3288 | (70.7%) | 50 | (55.6%) | 1173 | (66.7%) | 310 | (64.4%) |
pT | ||||||||
T1 | 2985 | (64.2%) | 49 | (54.4%) | 860 | (48.9%) | 286 | (59.5%) |
T2 | 1472 | (31.6%) | 38 | (42.2%) | 835 | (47.5%) | 184 | (38.3%) |
T3 | 184 | (4.0%) | 3 | (3.3%) | 62 | (3.5%) | 10 | (2.1%) |
T4 | 10 | (0.2%) | 0 | (0.0%) | 1 | (0.1%) | 1 | (0.2%) |
pN | ||||||||
N0 | 2717 | (58.4%) | 48 | (53.3%) | 1105 | (62.9%) | 303 | (63.0%) |
N1 | 1368 | (29.4%) | 29 | (32.2%) | 445 | (25.3%) | 129 | (26.8%) |
N2 | 363 | (7.8%) | 8 | (8.9%) | 133 | (7.6%) | 32 | (6.7%) |
N3 | 203 | (4.4%) | 5 | (5.6%) | 75 | (4.3%) | 17 | (3.5%) |
Stage | ||||||||
I | 2156 | (46.4%) | 32 | (35.6%) | 630 | (35.8%) | 210 | (43.7%) |
IIA | 1266 | (27.2%) | 30 | (33.3%) | 635 | (36.1%) | 162 | (33.7%) |
IIB | 605 | (13.0%) | 14 | (15.6%) | 266 | (15.1%) | 54 | (11.2%) |
IIIA | 413 | (8.9%) | 9 | (10.0%) | 151 | (8.6%) | 37 | (7.7%) |
IIIB | 8 | (0.2%) | 0 | 1 | (0.1%) | 1 | (0.2%) | |
IIIC | 203 | (4.4%) | 5 | (5.6%) | 75 | (4.3%) | 17 | (3.5%) |
Nuclear Grade | ||||||||
I | 974 | (21.0%) | 1 | (1.1%) | 12 | (0.7%) | 67 | (14.0%) |
II | 2656 | (57.3%) | 26 | (29.2%) | 358 | (20.4%) | 206 | (43.1%) |
III | 1006 | (21.7%) | 62 | (69.7%) | 1383 | (78.9%) | 205 | (42.9%) |
unknown | 15 | 1 | 5 | 3 | ||||
HER2 | ||||||||
Positive | 518 | (11.4%) | 30 | (34.5%) | 671 | (38.8%) | 159 | (34.5%) |
Negative | 4018 | (88.6%) | 57 | (65.5%) | 1058 | (61.2%) | 302 | (65.5%) |
Unknown | 115 | 3 | 29 | 20 | ||||
Ki-67 | ||||||||
≥ 14.0% | 2202 | (53.9%) | 56 | (91.8%) | 1334 | (93.9%) | 292 | (76.0%) |
< 14.0% | 1887 | (46.1%) | 5 | (8.2%) | 87 | (6.1%) | 92 | (24.0%) |
Unknown | 562 | 29 | 337 | 97 | ||||
p53 | ||||||||
Positive | 1008 | (21.8%) | 49 | (55.1%) | 1021 | (58.4%) | 162 | (34.2%) |
Negative | 3622 | (78.2%) | 40 | (44.9%) | 727 | (41.6%) | 311 | (65.8%) |
Unknown | 21 | 1 | 10 | 8 | ||||
Chemotherapy | ||||||||
Yes | 3127 | (68.7%) | 78 | (89.7%) | 1575 | (91.9%) | 345 | (73.7%) |
No | 1424 | (31.3%) | 9 | (10.3%) | 138 | (8.1%) | 123 | (26.3%) |
Unknown | 100 | 3 | 45 | 13 | ||||
Radiotherapy | ||||||||
Yes | 3543 | (78.0%) | 55 | (64.0%) | 1258 | (73.8%) | 334 | (70.9%) |
No | 1001 | (22.0%) | 31 | (36.0%) | 446 | (26.2%) | 137 | (29.1%) |
Unknown | 107 | 4 | 54 | 10 | ||||
Endocrine Therapy | ||||||||
Yes | 4490 | (99.2%) | 75 | (88.2%) | 2 | (0.1%) | 454 | (97.0%) |
No | 34 | (0.8%) | 10 | (11.8%) | 1704 | (99.9%) | 14 | (3.0%) |
Unknown | 127 | 5 | 52 | 13 | ||||